
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed Inc. is projected to experience substantial growth, with annual utilization per surgeon expected to rise from 5.8 in 2024 to approximately 9.7 over the next three years, supported by an expanding physician base of around 400 doctors. Lumbar revenue is estimated to reach around $121 million by 2028, alongside the anticipated introduction of Cervical solutions, which is expected to comprise 15% of overall revenue by the same year. Furthermore, the company's R&D investments are expected to yield significant returns, with incremental revenues outpacing the growth in R&D expenses, contributing to a projected revenue compound annual growth rate (CAGR) exceeding 50% from 2024 to 2028.
Bears say
Carlsmed Inc faces several challenges that could negatively impact its stock performance. The anticipated decline in average selling price per case, driven by an increasing mix of lower-priced cervical procedures, poses a risk to revenue projections, particularly as the company competes against larger players with broader portfolios. Additionally, potential slower adoption of its AI-enabled aprevo technology by surgeons, coupled with reimbursement changes that could adversely affect hospital economics, may hinder growth and put downward pressure on pricing.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares